Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

MLA

Boye, Kristina S., et al. “Generalizability of Glucagon-like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States.” Diabetes, Obesity & Metabolism, vol. 21, no. 6, June 2019, pp. 1299–304. EBSCOhost, https://doi.org/10.1111/dom.13649.

APA

Boye, K. S., Riddle, M. C., Gerstein, H. C., Mody, R., Garcia-Perez, L.-E., Karanikas, C. A., Lage, M. J., Riesmeyer, J. S., & Lakshmanan, M. C. (2019). Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes, Obesity & Metabolism, 21(6), 1299–1304. https://doi.org/10.1111/dom.13649

Chicago

Boye, Kristina S, Matthew C Riddle, Hertzel C Gerstein, Reema Mody, Luis-Emilio Garcia-Perez, Chrisanthi A Karanikas, Maureen J Lage, Jeffrey S Riesmeyer, and Mark C Lakshmanan. 2019. “Generalizability of Glucagon-like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States.” Diabetes, Obesity & Metabolism 21 (6): 1299–1304. doi:10.1111/dom.13649.